GRFS

Business Context and Reporting Period

Company: Grifols, S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter 2026 (Ended March 31, 2026)
Release Date: May 7, 2026
Business Overview: Grifols is a global healthcare company and leading producer of plasma-derived medicines, operating in over 110 countries. The company focuses on immunology, neurology, pulmonology, hematology, hepatology, and intensive care.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue grew 3.3% on a constant currency basis, driven primarily by the Biopharma segment (+6.8% cc). This growth was partially offset by foreign exchange headwinds (€144 million negative impact) and declines in other segments.
• Biopharma Performance: The Immunoglobulin (IG) franchise grew 15.3% cc, fueled by the U.S. launch of Yimmugo and sustained performance of Gamunex. Conversely, Albumin revenue declined 6.1% cc due to pricing pressure in China, and Alpha-1/Specialty Proteins declined 7.4% due to a tougher comparison base from prior year inventory buy-ins.
• Profitability: Group profit increased 21.9% to €73 million. Adjusted EBITDA remained flat on a reported basis but grew 0.8% cc, supported by a 7.7% cc reduction in OPEX and efficiency improvements.
• Cash Flow: Free cash flow pre-M&A improved by €30 million year-over-year, driven by working capital management, lower CAPEX, and reduced financial expenses.

Guidance, Outlook, and Strategic Initiatives

• Full-Year 2026 Guidance: Management confirmed that Q1 performance is aligned with expectations and reiterated full-year 2026 guidance.
• Capital Structure Optimization: Grifols successfully refinanced all 2027 debt maturities. This included an upsized Term Loan B (approx. €3 billion equivalent) and an increased revolving credit facility commitment (from $938 million to over $2 billion). The company also redeemed €500 million of its highest-cost 2030 bonds. There are no significant debt maturities until October 2028.
• Strategic Projects: The Egypt plasma project is on schedule, targeting 1 million liters in 2026 and up to 3 million liters by 2029. This initiative aims to optimize global plasma sourcing, reduce reliance on U.S. plasma for ex-U.S. markets, and structurally improve margins.
• Diagnostic Segment: Performance was impacted by the dissolution of the Quidel Ortho joint business. Grifols expects to receive €65 million in compensation over 2026–2028. The company is advancing its next-generation Blood Typing Solutions (BTS) platform, with a launch expected in Q2 2026.
• Credit Ratings: S&P upgraded the issuer credit rating to BB- with a stable outlook. Moody's and Fitch also improved ratings/outlooks, citing the strengthening financial profile.

Investor Verification Checklist

• China Albumin Pricing: Verify the sustainability of the pricing environment in China and the effectiveness of the SRAAS partnership in mitigating revenue declines.
• Egypt Project Timeline: Monitor the ramp-up of plasma collection in Egypt against the 1 million liter 2026 target to assess margin expansion potential.
• Debt Refinancing Terms: Review the specific interest rates and covenants of the new Term Loan B and Revolving Credit Facility to confirm the target of 2026 cash interest being in line with or better than 2025.
• Diagnostic Compensation: Track the receipt of the €65 million compensation from the Quidel Ortho dissolution and its impact on future cash flows.
• Alpha-1 Growth: Watch for the H2 2026 readout of the SPARTA phase 3 trial, which is identified as a potential inflection point for the Alpha-1 franchise.